IMM 1.61% 31.5¢ immutep limited

ovarian cancer drug fails , page-8

  1. 19 Posts.
    Definitely not downramping. My first thoughts on seeing the article where, as some posters agreed, that there is one less competitor which makes CVAC even more attractive. Sorry for the confusion.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.